SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Guy Gordon who wrote (312)5/6/1999 2:07:00 PM
From: LemurHouse  Read Replies (1) of 656
 
I originally bought into this stock last September as a short term play anticipating ENBREL approval in November. Had expected to sell on the news, and could have done so with a sizeable profit. But the more I looked at the company, the more I became convinced that it is a great medium/long term holding. It has a lot more going for it than just ENBREL (although that's a sizeable market in and of itself). Other products include Novantrone which will almost certainly be approved for chronic progressive MS within the next few months, Leukine, the cancer drug (also a CHF candidate), and in my view most promising of all (financially) is is their inhalable asthma drug Nuvance.

The company has always had great science, but now its moving from being just another promising biotech researcher to a profitable pharma company. So don't write it off just because its not a large cap!

Cheers.


PS: My cat also sits on my monitor. She doesn't read charts either -- she's too busy trying to hypnotize me, boring holes in my head with her eyes.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News